Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer

Breast cancer is the most common cancer affecting women and is the second leading cause of cancer related death worldwide. Angiogenesis, the process of new blood vessel development from pre-existing vasculature, has been implicated in the growth, progression, and metastasis of cancer. Tumor angiogen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jordan A. Harry, Mark L. Ormiston
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	angiogenesis breast cancer vascular endothelial growth factor bone morphogenetic protein 9 notch signaling Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/da7b78183d59404698636d023ca85abb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da7b78183d59404698636d023ca85abb
record_format	dspace
spelling	oai:doaj.org-article:da7b78183d59404698636d023ca85abb2021-12-03T07:16:03ZNovel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer2234-943X10.3389/fonc.2021.772305https://doaj.org/article/da7b78183d59404698636d023ca85abb2021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.772305/fullhttps://doaj.org/toc/2234-943XBreast cancer is the most common cancer affecting women and is the second leading cause of cancer related death worldwide. Angiogenesis, the process of new blood vessel development from pre-existing vasculature, has been implicated in the growth, progression, and metastasis of cancer. Tumor angiogenesis has been explored as a key therapeutic target for decades, as the blockade of this process holds the potential to reduce the oxygen and nutrient supplies that are required for tumor growth. However, many existing anti-angiogenic approaches, such as those targeting Vascular Endothelial Growth Factor, Notch, and Angiopoietin signaling, have been associated with severe side-effects, limited survival advantage, and enhanced cancer regrowth rates. To address these setbacks, alternative pathways involved in the regulation of tumor angiogenesis are being explored, including those involving Bone Morphogenetic Protein-9 signaling, the Sonic Hedgehog pathway, Cyclooxygenase-2, p38-mitogen-activated protein kinase, and Chemokine Ligand 18. This review article will introduce the concept of tumor angiogenesis in the context of breast cancer, followed by an overview of current anti-angiogenic therapies, associated resistance mechanisms and novel therapeutic targets.Jordan A. HarryMark L. OrmistonMark L. OrmistonMark L. OrmistonFrontiers Media S.A.articleangiogenesisbreast cancervascular endothelial growth factorbone morphogenetic protein 9notch signalingNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	angiogenesis breast cancer vascular endothelial growth factor bone morphogenetic protein 9 notch signaling Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	angiogenesis breast cancer vascular endothelial growth factor bone morphogenetic protein 9 notch signaling Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jordan A. Harry Mark L. Ormiston Mark L. Ormiston Mark L. Ormiston Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer
description	Breast cancer is the most common cancer affecting women and is the second leading cause of cancer related death worldwide. Angiogenesis, the process of new blood vessel development from pre-existing vasculature, has been implicated in the growth, progression, and metastasis of cancer. Tumor angiogenesis has been explored as a key therapeutic target for decades, as the blockade of this process holds the potential to reduce the oxygen and nutrient supplies that are required for tumor growth. However, many existing anti-angiogenic approaches, such as those targeting Vascular Endothelial Growth Factor, Notch, and Angiopoietin signaling, have been associated with severe side-effects, limited survival advantage, and enhanced cancer regrowth rates. To address these setbacks, alternative pathways involved in the regulation of tumor angiogenesis are being explored, including those involving Bone Morphogenetic Protein-9 signaling, the Sonic Hedgehog pathway, Cyclooxygenase-2, p38-mitogen-activated protein kinase, and Chemokine Ligand 18. This review article will introduce the concept of tumor angiogenesis in the context of breast cancer, followed by an overview of current anti-angiogenic therapies, associated resistance mechanisms and novel therapeutic targets.
format	article
author	Jordan A. Harry Mark L. Ormiston Mark L. Ormiston Mark L. Ormiston
author_facet	Jordan A. Harry Mark L. Ormiston Mark L. Ormiston Mark L. Ormiston
author_sort	Jordan A. Harry
title	Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer
title_short	Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer
title_full	Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer
title_fullStr	Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer
title_full_unstemmed	Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer
title_sort	novel pathways for targeting tumor angiogenesis in metastatic breast cancer
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/da7b78183d59404698636d023ca85abb
work_keys_str_mv	AT jordanaharry novelpathwaysfortargetingtumorangiogenesisinmetastaticbreastcancer AT marklormiston novelpathwaysfortargetingtumorangiogenesisinmetastaticbreastcancer AT marklormiston novelpathwaysfortargetingtumorangiogenesisinmetastaticbreastcancer AT marklormiston novelpathwaysfortargetingtumorangiogenesisinmetastaticbreastcancer
_version_	1718373843799638016

Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer

Ejemplares similares